Gallic acid

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog® as Groundbreaking Dietary Supplement for Cognitive Support

Retrieved on: 
Tuesday, March 26, 2024
Function (mathematics), Gallic acid, Attention, Brain, Ellagic acid, Longevity, Growth, Prevalence, Learning, BDNF, Science, Clinical, Memory, Disease, Name, Eternal, Ageing, Brain-derived neurotrophic factor, Marketing, Homocysteine, PLT, Food, Dietary supplement

MORRISTOWN, N.J., March 26, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced BioTRUST Nutrition® LLC, a leading eCommerce-based nutrition brand with a portfolio of high-quality, science-backed products focused on healthy aging and improving healthspan, has introduced a new product targeted at providing brain longevity and cognitive support called Eternal Mind®. The new product features PLT's Nutricog® Cognitive Performance Complex, an ingredient that has been clinically demonstrated to provide significant improvements across multiple cognitive domains, including learning, memory, attention, focus, and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. In addition, clinical science showed that Nutricog doubled levels brain-derived neurotrophic factor (BDNF), a neuroprotein involved in the brain's ability to adapt to new information.

Key Points: 
  • Eternal Mind is available direct-to-consumer from the BioTRUST Nutrition website ( www.biotrust.com ) and via Amazon.
  • "Brain and cognitive health are a significant concern for many Americans, especially as we age.
  • However, navigating the cognitive supplement market can be challenging due to the prevalence of expensive products with ambiguous 'proprietary blends' and vague claims," Chris Marschall said.
  • According to BioTRUST®, Eternal Mind is backed by the latest science in brain health.

Danone North America Selects Fellowship Grant Recipients to Propel Gut Microbiome, Yogurt and Probiotic Research Forward

Retrieved on: 
Tuesday, May 9, 2023
Gallic acid, Food, University, Bureau of Oceans and International Environmental and Scientific Affairs, NGP, Probiotic, Harvard University, PBC, University of Texas at Austin, Research, Brain, Doctor of Philosophy, Gut–brain axis, Danone, White House conference, Investment, Yogurt, Immune system, Danone North America, Biology, Knowledge, Faculty, Ecosystem, Food security, Conference, Dietary supplement, Health, Hunger

WHITE PLAINS, N.Y., May 9, 2023 /PRNewswire/ -- Danone North America, the purpose-driven food and beverage leader, is proud to announce it has selected this year's recipients of the 2022-2023 Annual Gut Microbiome, Yogurt and Probiotic Fellowship Program. This year, Madison Adamthwaite of Harvard University and Nam Than of The University of Texas at Austin have been awarded $25,000 each to conduct research which will help to further the understanding of the Gut Microbiome, Yogurt and Probiotics. The 2022-2023 program marks eleven years and over half a million dollars' worth of grants awarded to empower creative minds and nurture scientific advances.

Key Points: 
  • The impact of yogurt, probiotics and the gut microbiome may be linked to full-body health impacts including brain, digestive and immune function.
  • "It is Danone North America's mission to bring health through food to as many people as possible and this fellowship grant helps us do just that," said Miguel Freitas, PhD, Vice President of Health and Scientific Affairs at Danone North America.
  • The Danone Fellowship Grant was established in 2010 to provide funding for novel studies of yogurt, probiotics, and the gut microbiome.
  • The 2023 Fellowship Grants for Gut Microbiome, Yogurt and Probiotic studies are a part of this commitment.

PLT Introduces Novel, Botanical Cognitive Performance Ingredient with a Broad Set of Benefits

Retrieved on: 
Monday, February 27, 2023
Recognition memory, Female, Athens insomnia scale, Overalls, Learning, Function (mathematics), Ellagic acid, Produce traceability, Episodic, Long-term memory, Amyrin, Brain, BDNF, Episodic memory, Innovation, Memory, Gallic acid, Brain-derived neurotrophic factor, Rate, Male, Short-term memory, PLT, PAI, Concentration, Learning rate, Theory, Working memory, Cambridge Neuropsychological Test Automated Battery, Ageing, Nursing, Pharmaceutical industry, CANTAB, Boswellia, RD, Recognition

MORRISTOWN, N.J., Feb. 27, 2023 /PRNewswire/ -- PLT Health Solutions, Inc is launching a novel ingredient to support a broad range of cognitive performance abilities. Called Nutricog® Cognitive Performance Complex, it is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) — standardized to gallic acid, ellagic acid and amyrins. In a randomized, double-blind, placebo-controlled clinical trial, users of Nutricog demonstrated significant improvements compared to placebo across multiple cognitive domains, including learning, memory, sustained attention, working memory and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. The earliest clinically significant benefits (memory and focus) for Nutricog were shown to start at just 15 days after commencing use. PLT is introducing Nutricog at Natural Products Expo West in March and at Vitafoods Europe in May.

Key Points: 
  • Called Nutricog® Cognitive Performance Complex, it is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) — standardized to gallic acid, ellagic acid and amyrins.
  • According to Seth Flowerman, President & CEO of PLT Health Solutions, the new ingredient was developed in response to consumer interest in maximizing cognitive support as a quality-of-life issue.
  • "Today, we are seeing rapidly increasing interest in cognitive support for a broad range of lifestyle goals.
  • At PLT, we're very excited to be introducing Nutricog to the market after more than five years in development.

Pharmactive: Carob Extract Helps Restore Syndrome X Cardiometabolic Alterations

Retrieved on: 
Tuesday, November 22, 2022
Mineral, Doctor of Philosophy, University, Metabolism, Adiponectin, Mouse, Calcium, Gene expression, Syndrome X, TNF, Degenerative disease, Metabolic syndrome, Metadata, Liver, CSAT, Weight loss, Drink, Abdominal obesity, Autonomous university, IL6, Potassium, Research, Gallic acid, Organic acid, Type, Blood pressure, Autonomous University of Madrid, Oxidative stress, Type 2 diabetes, SLU, Insulin resistance, Polyphenol, Iron, Exercise, Seed, Legume, Dietary supplement, Antioxidant

MADRID, Nov. 22, 2022 /PRNewswire/ -- Supplementation with the proprietary carob seed and pod extract CSAT+®, by Pharmactive Bioactive Products, SLU, combined with a low-calorie diet and aerobic training, could help reverse some of the cardiometabolic alterations associated with Metabolic Syndrome, according to results of a new animal study.

Key Points: 
  • Metabolic Syndrome (MetS),also known as Syndrome X, is characterized by a cluster of riskfactors, such as high triglycerides, unbalanced cholesterol levels, abdominal obesity, insulin resistance, and high blood pressure.
  • The goal was toinvestigate whether supplementation with Pharmactive's CSAT+, alone or in combination with aerobic training, accelerates the restorationof cardiometabolic health in caloric-restricted mice with MetS.
  • Standardized to at least 36% galactomannans, 2% oligofructose, and 1% polyphenols, CSAT+ carob extract is grown in Spain.
  • With high standards and dedicated R&D investment, Pharmactive was the first company to introduce saffron extract for mood improvement.

Pharmactive: Carob Extract Helps Restore Syndrome X Cardiometabolic Alterations

Retrieved on: 
Tuesday, November 22, 2022
Mineral, Doctor of Philosophy, University, Metabolism, Adiponectin, Mouse, Calcium, Gene expression, Syndrome X, TNF, Degenerative disease, Metabolic syndrome, Metadata, Liver, CSAT, Weight loss, Drink, Abdominal obesity, Autonomous university, IL6, Potassium, Research, Gallic acid, Organic acid, Type, Blood pressure, Autonomous University of Madrid, Oxidative stress, Type 2 diabetes, SLU, Insulin resistance, Polyphenol, Iron, Exercise, Seed, Legume, Dietary supplement, Antioxidant

MADRID, Nov. 22, 2022 /PRNewswire/ -- Supplementation with the proprietary carob seed and pod extract CSAT+®, by Pharmactive Bioactive Products, SLU, combined with a low-calorie diet and aerobic training, could help reverse some of the cardiometabolic alterations associated with Metabolic Syndrome, according to results of a new animal study.

Key Points: 
  • Metabolic Syndrome (MetS),also known as Syndrome X, is characterized by a cluster of riskfactors, such as high triglycerides, unbalanced cholesterol levels, abdominal obesity, insulin resistance, and high blood pressure.
  • The goal was toinvestigate whether supplementation with Pharmactive's CSAT+, alone or in combination with aerobic training, accelerates the restorationof cardiometabolic health in caloric-restricted mice with MetS.
  • Standardized to at least 36% galactomannans, 2% oligofructose, and 1% polyphenols, CSAT+ carob extract is grown in Spain.
  • With high standards and dedicated R&D investment, Pharmactive was the first company to introduce saffron extract for mood improvement.

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology

Retrieved on: 
Tuesday, June 28, 2022
EHF, EVD, Research, Polyphenol, GLOBE, RT-PCR, Marketing, COVID-19, Laboratory, Chromosome, TK, Genomics, CLIA, World, DSS, Environment, IND, Prophase, Nebula Genomics, Federal Food, Drug, and Cosmetic Act, GRAS, Severe acute respiratory syndrome coronavirus 2, FDA, University, Gene, Food, LLC, SEC, Risk, Solution, Global, Institution, Acquisition, OTC, Biotechnology, Infection, Dietary supplement, COVID-19 testing, Baxter International, Private Securities Litigation Reform Act, Nasdaq, Health, NASDAQ, PCR, Drug discovery, Ebola, Gallic acid, Inherited disorders of trafficking, FDM, R, Charles River Laboratories, Degenerative disease, Mass, World Health Organization, DNA, Human, Safety, Vaccine, Pharmaceutical industry, Antibiotics, Company, Rhinovirus, Gallic

Garden City, NY, June 28, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced the formation of wholly-owned subsidiary ProPhase BioPharma, Inc. (PBIO) for the licensing and development of novel drugs, compounds and biotechnology. PBIO will focus on advanced technology in the biochemical industry and creating and formulating new compounds that can change the outcomes of healthcare.

Key Points: 
  • Under the terms of the agreement, ProPhase Labs has obtained exclusive rights worldwide to develop and commercialize Equivir and Equivir G.
    We are thrilled to announce the formation of ProPhase BioPharma, our new wholly-owned subsidiary tasked with licensing and developing novel drugs, compounds and biotechnology.
  • We also look forward to applying to the FDA for an IND for Equivir G as a prescription antiviral.
  • The agreement between ProPhase Labs and Global BioLife comes just prior to the commencement of human clinical trials for Equivir.
  • ProPhase is currently in contact with leading clinical research organizations to initiate these trials in the coming months.

Gallic Acid Market 2019, Global Key Manufacturers, Demands, Sales, Production Value and Forecasts to 2024 - ReportsnReports

Retrieved on: 
Monday, December 9, 2019
Gallic acid, Gallotannins, Market research, Compound annual growth rate, Marketplace, Academic disciplines, Organic compounds, Chemical substances

Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

Key Points: 
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Global Gallic Acid Market Growth 2019-2024- Over the next five years the Gallic Acid (CAS 149-91-7) market will register a 7.6% CAGR in terms of revenue, the global market size will reach US$ 82 million by 2024, from US$ 61 million in 2019.
  • In particular, this report presents the global market share (sales and revenue) of key companies in Gallic Acid (CAS 149-91-7) business.
  • Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Gallic Acid Market 2019, Global Key Manufacturers, Demands, Sales, Production Value and Forecasts to 2024 - ReportsnReports

Retrieved on: 
Monday, December 9, 2019
Gallic acid, Gallotannins, Market research, Compound annual growth rate, Marketplace, Academic disciplines, Organic compounds, Chemical substances

Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

Key Points: 
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Global Gallic Acid Market Growth 2019-2024- Over the next five years the Gallic Acid (CAS 149-91-7) market will register a 7.6% CAGR in terms of revenue, the global market size will reach US$ 82 million by 2024, from US$ 61 million in 2019.
  • In particular, this report presents the global market share (sales and revenue) of key companies in Gallic Acid (CAS 149-91-7) business.
  • Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Global Gallic Acid Market by Type, Application & Region - Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 12, 2019
Chemicals, Plastics, Manufacturing, Branches of biology, Chemical substances, Gallotannins, Physical sciences, Gallic acid, Mutagen, Antioxidant, Gallic

The "Global Gallic Acid Market, By Type, By Applications, By Region; Size and Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gallic Acid Market, By Type, By Applications, By Region; Size and Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
  • Application of Gallic Acid to make dyes for leather and hair products make dyes for leather and hair products and use of Gallic acid being anti-microbial, anti-carcinogenic, and anti-mutagenic and antioxidant in food industry will increase the global Gallic Acid market in upcoming year.
  • Moreover, use of Gallic Acid pharmacology to impart medicinal properties that are hepatoprotective and neuroprotective and Gallic Acid as anti-carcinogenic and anti-microbial make it an important intermediary which will drive the promising future of Gallic acid market in the pharmaceutical and therapeutic industry.
  • North America dominates the world Gallic Acid market over the forecast period owing to major demand of Gallic Acid from Pharmaceuticals and food Industry.